PubMed RSS Feed - -A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema

[rss]

Dermatol Ther. 2022 Jan 20:e15327. doi: 10.1111/dth.15327. Online ahead of print.

ABSTRACT

BACKGROUND: persistent post acne erythema (PAE) is a common cosmetically unacceptable and challenging sequelae of acne lesions. Tranexamic acid (TXA) is an antifibrinolytic agent that shows a positive effect on wound healing in several studies, and it showed benefits in treating skin diseases like melasma, rosacea erythema and ultraviolet induced pigmentations. Oxymetazoline (OXZ) is a synthetic, highly selective agonist for alpha 1A-adrenoceptor. It is a potent vasoconstrictor. Oxymetazoline hydrochloride 1% cream was approved by the FDA in January 2017 as a topical treatment for persistent facial erythema in rosacea patients. Brimonidine tartrate (BR) is highly selective α₂ adrenergic receptor agonist, results in direct, potent vasoconstriction of small arterioles and veins. In 2013, brimonidine 0.33% gel was the first topical therapy to be FDA approved for the treatment of persistent facial erythema from rosacea.

OBJECTIVES: to evaluate the efficacy and safety of topical triple combination (TXA 5%+OXZ 1.5%+ BMT 0.33%) in the treatment of post acne erythema (PAE) planned as split face comparative study.

METHODS: This study was conducted on 40 patients diagnosed with persistent post acne erythema for at least 3 months, the right side of the face was treated with topical triple combination in liposomal base and was compared to the left side to which topical lipocream (placebo) was applied as a control. Our treatment plan lasted for 3 months.

RESULTS: According to the investigator's global assessment of photographs and computerized analysis of erythema using image analysis software, topical triple combination applied o the right side of face was significantly effective in diminishing PAE when compared to topical placebo left side.

CONCLUSION: topical triple combination is a safe and cost-effective treatment for post-acne erythema.

PMID:35060229 | DOI:10.1111/dth.15327

{url} = URL to article